DK1303490T3 - N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater - Google Patents
N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivaterInfo
- Publication number
- DK1303490T3 DK1303490T3 DK01949475T DK01949475T DK1303490T3 DK 1303490 T3 DK1303490 T3 DK 1303490T3 DK 01949475 T DK01949475 T DK 01949475T DK 01949475 T DK01949475 T DK 01949475T DK 1303490 T3 DK1303490 T3 DK 1303490T3
- Authority
- DK
- Denmark
- Prior art keywords
- antagonic
- receptor
- oxides
- phenyl
- products
- Prior art date
Links
- 150000005362 4-phenylpyridines Chemical class 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 title 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00115287 | 2000-07-14 | ||
| PCT/EP2001/007850 WO2002006236A1 (en) | 2000-07-14 | 2001-07-09 | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1303490T3 true DK1303490T3 (da) | 2008-08-25 |
Family
ID=8169262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01949475T DK1303490T3 (da) | 2000-07-14 | 2001-07-09 | N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater |
Country Status (38)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2208205T3 (es) * | 1999-11-29 | 2004-06-16 | F. Hoffmann-La Roche Ag | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida. |
| HRP20030003B1 (en) * | 2000-07-14 | 2011-01-31 | F. Hoffmann - La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| EP1385577B1 (en) * | 2001-04-23 | 2006-04-19 | F. Hoffman-la Roche AG | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| ES2291891T3 (es) | 2003-07-03 | 2008-03-01 | F. Hoffmann-La Roche Ag | Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia. |
| WO2006002860A1 (en) | 2004-07-06 | 2006-01-12 | F. Hoffmann-La Roche Ag | Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists |
| US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| WO2006089674A2 (en) | 2005-02-25 | 2006-08-31 | F.Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
| DE602006005624D1 (de) * | 2005-03-23 | 2009-04-23 | Hoffmann La Roche | Metaboliten für nk-i-antagonisten zur emesis |
| JP2008280248A (ja) * | 2005-11-02 | 2008-11-20 | Eisai R & D Management Co Ltd | アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ |
| AU2008208920A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1 |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| US8966414B2 (en) | 2009-05-29 | 2015-02-24 | Cypress Semiconductor Corporation | Implementing a circuit using an integrated circuit including parametric analog elements |
| US9858367B1 (en) * | 2009-08-31 | 2018-01-02 | Cypress Semiconductor Corporation | Integrated circuit including parametric analog elements |
| PH12012500887A1 (en) | 2009-11-18 | 2016-08-26 | Helsinn Healthcare Sa | Compositions for treating centrally mediated nausea and vomiting |
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| CN106974912A (zh) | 2011-10-18 | 2017-07-25 | 赫尔辛医疗股份公司 | 奈妥匹坦和帕洛诺司琼的治疗性组合 |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PT3141542T (pt) | 2011-12-28 | 2020-06-16 | Global Blood Therapeutics Inc | Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
| ES2890077T3 (es) * | 2013-03-15 | 2022-01-17 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237340C1 (en) | 2013-03-15 | 2018-11-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| JP5806420B1 (ja) | 2013-11-08 | 2015-11-10 | キッセイ薬品工業株式会社 | カルボキシメチルピペリジン誘導体 |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US10350098B2 (en) * | 2013-12-20 | 2019-07-16 | Volcano Corporation | Devices and methods for controlled endoluminal filter deployment |
| PL3102208T5 (pl) | 2014-02-07 | 2024-10-14 | Global Blood Therapeutics, Inc. | Krystaliczny polimorf wolnej zasady 2-hydroksy-6-((2-(1-izopropylo-1h-pirazol-5-ilo)pirydyn-3-ylo)metoksy)benzaldehydu |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| CN106588899B (zh) * | 2015-10-15 | 2019-11-15 | 江苏恒瑞医药股份有限公司 | 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用 |
| PL3383392T3 (pl) | 2015-12-04 | 2025-11-17 | Global Blood Therapeutics, Inc. | Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| KR20200026920A (ko) | 2017-06-30 | 2020-03-11 | 체이스 테라퓨틱스 코포레이션 | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 |
| ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56106286A (en) | 1980-01-28 | 1981-08-24 | Nippon Musical Instruments Mfg | Electronic musical instrument |
| EP0103545A3 (en) | 1982-09-13 | 1984-10-03 | Arc Technologies Systems, Ltd. | Electrode for arc furnaces |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| CN1067683C (zh) | 1993-12-29 | 2001-06-27 | 默克·夏普-道姆公司 | 取代的吗啉衍生物及其作为治疗剂的用途 |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| IL144717A0 (en) * | 1999-02-24 | 2002-06-30 | Hoffmann La Roche | Phenyl-and pyridinyl derivatives |
| DK1035115T3 (da) * | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
| TR200102489T2 (tr) * | 1999-02-24 | 2002-04-22 | F.Hoffmann-La Roche Ag | 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması |
| ES2208205T3 (es) * | 1999-11-29 | 2004-06-16 | F. Hoffmann-La Roche Ag | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida. |
| HRP20030003B1 (en) * | 2000-07-14 | 2011-01-31 | F. Hoffmann - La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
-
2001
- 2001-07-09 HR HR20030003A patent/HRP20030003B1/xx not_active IP Right Cessation
- 2001-07-09 MX MXPA03000366A patent/MXPA03000366A/es active IP Right Grant
- 2001-07-09 CA CA002415890A patent/CA2415890C/en not_active Expired - Lifetime
- 2001-07-09 SI SI200130848T patent/SI1303490T1/sl unknown
- 2001-07-09 AT AT01949475T patent/ATE400556T1/de active
- 2001-07-09 RS YUP-6/03A patent/RS50932B/sr unknown
- 2001-07-09 EP EP01949475A patent/EP1303490B1/en not_active Expired - Lifetime
- 2001-07-09 JP JP2002512140A patent/JP3950044B2/ja not_active Expired - Lifetime
- 2001-07-09 ES ES01949475T patent/ES2309075T3/es not_active Expired - Lifetime
- 2001-07-09 NZ NZ523273A patent/NZ523273A/en not_active IP Right Cessation
- 2001-07-09 RU RU2003102612/04A patent/RU2266284C2/ru active
- 2001-07-09 DE DE60134749T patent/DE60134749D1/de not_active Expired - Lifetime
- 2001-07-09 AU AU7061901A patent/AU7061901A/xx active Pending
- 2001-07-09 PL PL365684A patent/PL205207B1/pl unknown
- 2001-07-09 WO PCT/EP2001/007850 patent/WO2002006236A1/en not_active Ceased
- 2001-07-09 CN CNB018128246A patent/CN1178917C/zh not_active Expired - Lifetime
- 2001-07-09 CZ CZ20030428A patent/CZ303639B6/cs not_active IP Right Cessation
- 2001-07-09 KR KR10-2003-7000476A patent/KR100501608B1/ko not_active Expired - Lifetime
- 2001-07-09 ME MEP-2008-770A patent/ME01311B/me unknown
- 2001-07-09 IL IL15383401A patent/IL153834A0/xx unknown
- 2001-07-09 HU HU0301311A patent/HU230316B1/hu unknown
- 2001-07-09 BR BRPI0112475A patent/BRPI0112475B8/pt not_active IP Right Cessation
- 2001-07-09 PT PT01949475T patent/PT1303490E/pt unknown
- 2001-07-09 DK DK01949475T patent/DK1303490T3/da active
- 2001-07-10 JO JO2001106A patent/JO2372B1/en active
- 2001-07-11 EG EG2001070771A patent/EG24968A/xx active
- 2001-07-11 PA PA20018522001A patent/PA8522001A1/es unknown
- 2001-07-12 US US09/904,059 patent/US6593472B2/en not_active Expired - Lifetime
- 2001-07-12 MY MYPI20013310A patent/MY154976A/en unknown
- 2001-07-12 GT GT200100137A patent/GT200100137A/es unknown
- 2001-07-13 PE PE2001000704A patent/PE20020272A1/es active IP Right Grant
- 2001-07-13 UY UY26839A patent/UY26839A1/es not_active IP Right Cessation
- 2001-07-13 AR ARP010103335A patent/AR029717A1/es active IP Right Grant
-
2002
- 2002-12-17 ZA ZA200210207A patent/ZA200210207B/en unknown
-
2003
- 2003-01-07 IL IL153834A patent/IL153834A/en active IP Right Grant
- 2003-01-07 US US10/337,543 patent/US6747026B2/en not_active Expired - Lifetime
- 2003-01-13 MA MA26997A patent/MA26929A1/fr unknown
- 2003-01-13 NO NO20030154A patent/NO324700B1/no not_active IP Right Cessation
- 2003-01-14 EC EC2003004431A patent/ECSP034431A/es unknown
- 2003-07-09 US US10/616,276 patent/US6897226B2/en not_active Expired - Lifetime
- 2003-08-21 US US10/645,895 patent/US6806370B2/en not_active Expired - Lifetime
-
2008
- 2008-10-07 CY CY20081101108T patent/CY1108557T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1303490T3 (da) | N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater | |
| DK1309559T3 (da) | 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister | |
| NO20015365L (no) | Piperidinderivater som er anvendbare som CCR5-antagonister | |
| NO20015366L (no) | Piperazinderivater som er anvendbare som CCR5-antagonister | |
| PT1343786E (pt) | Novos derivados de pirazolopiridina substituidos por piridina | |
| DK2258688T3 (da) | Pyridinon-derivater til behandling af aterosklerose | |
| DK1224175T3 (da) | Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister | |
| DK1404667T3 (da) | Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet | |
| DK1394150T3 (da) | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister | |
| DK1157005T3 (da) | 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister | |
| DK1305319T3 (da) | 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister | |
| NO20032142L (no) | Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister | |
| NO20025136D0 (no) | Cykloheksylaminderivat som subtype selektive NMDA- reseptorantagonister | |
| NO20023293D0 (no) | Piperidin- og piperazinderivater som virker som 5-HT2A- reseptorantagonister | |
| DK1360184T3 (da) | Piperidinderivater som neurokinin-1-antagonister | |
| DK0964863T3 (da) | Oxazolidinoner som 5-HT2A-antagonister | |
| NO20014356D0 (no) | Bifenylderivater som antagonister av neurokinin-1 reseptoren | |
| NO20013709D0 (no) | Nye N-triazolylmetyl-piperazinderivater som neurokininreseptorantagonister | |
| DK1347974T3 (da) | Aminotriazolopyridinderivater som adenosinreceptorligander | |
| DK0933362T3 (da) | Fremgangsmåde til fremstilling af pyridindicarboxylatderivater | |
| DK1294694T3 (da) | Fremgangsmåde til fremstilling af quinolinderivater | |
| DK1289996T3 (da) | Heteroaryldiazabicycloalkaner som nicotiniske cholinergiske receptorligander | |
| DK1200402T3 (da) | Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande | |
| DK1347958T3 (da) | Fremgangsmåde til fremstilling af distamycinderivter | |
| DK1171419T3 (da) | Biphenylderivater som antagonister til Neurokinin-1-receptoren |